A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT...

Update Il y a 5 ans
Reference: EUCTR2009-009214-40

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Determine if the addition of filibuvir to a standard of care (SOC) regimen of pegylated interferon alpha 2a (Pegasys) and ribavirin (Copegus) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) - undetectable HCV RNA at week 72 compared to pegIFN/RBV alone.


Inclusion criteria

  • Treatment of chronic HCV genotype 1 infection